XAB2 and melanoma: The result showed that SMARCA4, XAB2 and NUDT1 were potent markers for the overall survival (OS) and disease‐specific survival (DSS) (Figure 2E–F) and SMARCA4 was shown to correlate with XAB2 and NUDT1 expression in melanoma patients (Figure 2G).